Palatin Technologies swings to FY27 first-quarter net loss of $5.06 million
PTN•Palatin Technologies reported a fiscal first-quarter net loss of $5.06 million, compared with net income of $4.68 million a year earlier. Revenue fell 96% to $361,802, and cash was $3.74 million at September 30, 2026; the company said additional funding is required and substantial doubt exists about its ability to continue as a going concern.
1. Quarterly results
Palatin Technologies swung to a fiscal first-quarter net loss of $5.06 million from net income of $4.68 million in the year-earlier period. Collaboration and license revenue fell 96% year over year to $361,802; the prior-year period included upfront and milestone payments.
2. Cash and development plans
Cash and cash equivalents declined 50% from June 30 to $3.74 million at September 30, 2026. The company said it requires additional funding for planned development and operations and that substantial doubt exists about its ability to continue as a going concern. It is targeting Phase 1 starts for its long-acting MC4R peptide in the first half of 2027 and its oral small molecule in the second half.




